Subscribe to RSS
DOI: 10.1055/a-2771-7960
Challenges of Implementing the “Watch” in Watch-and-Wait for Rectal Cancer
Authors
Abstract
Nonoperative management, or watch-and-wait, is an increasingly utilized treatment strategy for locally advanced rectal cancer both in the United States and internationally. Studies demonstrate acceptable oncologic outcomes for patients with clinical complete response (cCR) and close surveillance compared with those who undergo surgery after neoadjuvant therapy, but this strategy relies on multiple key factors to achieve optimal outcomes. Implementing watch-and-wait raises new challenges throughout the course of rectal cancer care, from treatment decision-making and offering watch-and-wait, throughout the course of surveillance which involves patients, providers, systems, and policy.
Publication History
Article published online:
09 January 2026
© 2026. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
- 2 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
- 3 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
- 4 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology for Rectal Cancer V 2.2025. © National Comprehensive Cancer Network, Inc.; 2024
- 5 Alvarez JA, Shi Q, Dasari A. et al Alliance A022104/NRG-GI010: The Janus rectal cancer trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer 2024; 24 (01) 901
- 6 Than NW, Pritchard DM, Duckworth CA. et al. Contact X-ray brachytherapy (CXB) as a salvage treatment for rectal cancer patients who developed local tumor re-growth after watch-and-wait approach. J Contemp Brachytherapy 2024; 16 (02) 95-102
- 7 Baron D, Pace Loscos T, Schiappa R. et al; ICONE group. A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. Ann Oncol 2025; 36 (02) 208-215
- 8 Custers PA, van der Sande ME, Grotenhuis BA. et al; Dutch Watch-and-Wait Consortium. Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach. JAMA Surg 2023; 158 (05) e230146
- 9 Loria A, Tejani MA, Temple LK. et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020. JAMA Oncol 2024; 10 (01) 79-86
- 10 Loria A, Ramsdale EE, Aquina CT, Cupertino P, Mohile SG, Fleming FJ. From clinical trials to practice: anticipating and overcoming challenges in implementing watch-and-wait for rectal cancer. J Clin Oncol 2024; 42 (08) 876-880
- 11 Ivatury SJ, Suwanabol PA, Roo AC. Shared decision-making, sphincter preservation, and rectal cancer treatment: identifying and executing what matters most to patients. Clin Colon Rectal Surg 2023; 37 (04) 256-265
- 12 Abelson JS, Gaetani RS, Hawkins AT. Shared decision making in the treatment of rectal cancer. J Clin Med 2025; 14 (07) 2255
- 13 Smits LJH, van Lieshout AS, Debets S. et al. Patients' perspectives and the perceptions of healthcare providers in the treatment of early rectal cancer; a qualitative study. BMC Cancer 2023; 23 (01) 1266
- 14 Rivard SJ, Vitous CA, Bamdad MC, Varlamos C, Duby A, Suwanabol PA. “Their whole lives are going to change”: a photo-elicitation study of rectal cancer survivorship. Dis Colon Rectum 2022; 65 (12) 1456-1463
- 15 Emmertsen KJ, Laurberg S. Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg 2013; 100 (10) 1377-1387
- 16 Juul T, Ahlberg M, Biondo S. et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum 2014; 57 (05) 585-591
- 17 Kaul S, Rao C, Mane R. et al. Is the management of rectal cancer using a watch and wait approach feasible, safe and effective in a publicly funded general hospital?. Clin Oncol (R Coll Radiol) 2022; 34 (01) e25-e34
- 18 Hupkens BJP, Martens MH, Stoot JH. et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum 2017; 60 (10) 1032-1040
- 19 Rooney MK, De B, Corrigan K. et al. Patient-reported bowel function and bowel-related quality of life after pelvic radiation for rectal adenocarcinoma: the impact of radiation fractionation and surgical resection. Clin Colorectal Cancer 2023; 22 (02) 211-221
- 20 Jones HJS, Al-Najami I, Cunningham C. Quality of life after rectal-preserving treatment of rectal cancer. Eur J Surg Oncol 2020; 46 (11) 2050-2056
- 21 Bulens PP, Smets L, Debucquoy A. et al. Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: a prospective cohort study. Clin Transl Radiat Oncol 2022; 36: 113-120
- 22 Gani C, Gani N, Zschaeck S. et al. Organ preservation in rectal cancer: the patients' perspective. Front Oncol 2019; 9: 318
- 23 Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010; 53 (12) 1692-1698
- 24 Maas M, Lambregts DM, Nelemans PJ. et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 2015; 22 (12) 3873-3880
- 25 Hupkens BJP, Maas M, Martens MH. et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?. Ann Surg Oncol 2018; 25 (01) 197-203
- 26 Custers PA, Geubels BM, Beets GL. et al. Defining near-complete response following (chemo)radiotherapy for rectal cancer: systematic review. Br J Surg 2022; 110 (01) 43-49
- 27 van der Sande ME, Maas M, Melenhorst J, Breukink SO, van Leerdam ME, Beets GL. Predictive value of endoscopic features for a complete response after chemoradiotherapy for rectal cancer. Ann Surg 2021; 274 (06) e541-e547
- 28 Sclafani F, Brown G, Cunningham D. et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer 2017; 117 (10) 1478-1485
- 29 Lambregts DM, Vandecaveye V, Barbaro B. et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011; 18 (08) 2224-2231
- 30 Sassen S, de Booij M, Sosef M. et al. Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?. Eur Radiol 2013; 23 (12) 3440-3449
- 31 Bhutiani N, Ochiai K, Peacock O. et al. Risk factors for regrowth after nonoperative management for rectal cancer. Ann Surg Oncol 2025; 32 (05) 3098-3105
- 32 Chadi SA, Malcomson L, Ensor J. et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (12) 825-836
- 33 Bach SP. STAR-TREC: an international three-arm multicentre, partially randomised controlled trial incorporating an external pilot. Clin Oncol (R Coll Radiol) 2023; 35 (02) e107-e109
- 34 Nasim BW, Murphy S, Yracheta J. et al. Barriers to offering organ preservation for rectal cancer in a predominantly Hispanic safety net hospital. J Surg Oncol 2025; 131 (02) 183-188
- 35 Voogt ELK, Nordkamp S, van Zoggel DMGI. et al. MRI tumour regression grade in locally recurrent rectal cancer. BJS Open 2022; 6 (03) zrac033
- 36 Society of Abdominal Radiology. Standardized MRI Rectum Restaging Template. Abdominal Radiology; 2025. Accessed December 30, 2025 at: https://abdominalradiology.org/wp-content/uploads/2025/03/Standardized-MRI-rectum-restaging-template-by-the-Society-of-Abdominal-Radiology.docx
- 37 Nougaret S, Rousset P, Lambregts DMJ. et al. MRI restaging of rectal cancer: the RAC (Response-Anal canal-CRM) analysis joint consensus guidelines of the GRERCAR and GRECCAR groups. Diagn Interv Imaging 2023; 104 (7-8): 311-322
- 38 Duldulao MP, Lee W, Streja L. et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum 2013; 56 (02) 142-149
- 39 Yeung TM, Rosen RY, Bercz A. et al; Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center. The value of MRI and flexible sigmoidoscopy in detecting tumor regrowth in watch and wait rectal cancer patients undergoing active surveillance after total neoadjuvant therapy. Surg Endosc 2025; 39 (09) 5669-5675
- 40 Haak HE, Žmuc J, Lambregts DMJ. et al; Dutch Watch-and-Wait Consortium. The evaluation of follow-up strategies of watch-and-wait patients with a complete response after neoadjuvant therapy in rectal cancer. Colorectal Dis 2021; 23 (07) 1785-1792
- 41 Hilty Chu BK, Loria A, Dhimal T. et al. Challenges of surveillance in implementing nonoperative management for rectal cancer. JAMA Netw Open 2024; 7 (12) e2448682
- 42 Rubens M, Oduyale O, Eltahir AA. et al. “Watch-and-wait” or “lost to follow-up”? Adherence to nonoperative management of rectal cancer. J Surg Res 2025; 311: 273-279
- 43 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (05) 487-497
- 44 Kini V, Ho PM. Interventions to improve medication adherence: a review. JAMA 2018; 320 (23) 2461-2473
- 45 Khatri R, Quinn PL, Wells-Di Gregorio S, Pawlik TM, Cloyd JM. Surveillance-associated anxiety after curative-intent cancer surgery: a systematic review. Ann Surg Oncol 2025; 32 (01) 47-62
- 46 Schroeder SA, Frist W. National Commission on Physician Payment Reform. Phasing out fee-for-service payment. N Engl J Med 2013; 368 (21) 2029-2032
- 47 Lai SH, Widmar M, Monson JRT, Fleming FJ, Morris AM, Vogel JD. Rectal cancer watch & wait management: experience of 545 patients from the U.S. Rectal Cancer Research Group. Dis Colon Rectum 2025 68 (02) 180-189
